Calcineurin may play a significant role in the modulation of nociception. Calcineurin may contribute to maintaining aspects of "normal" baseline physiologic sensory neural and/or glial function, via its role in maintaining "homeostatic potassium currents of resting membrane potentials." Furthermore, it appears that interruption of this valuable role of calcineurin may spark nociceptive processes and/or hyperexcitability and hence, may be involved in nociceptive signaling pathways, thereby potentially facilitating algesia.

The 2-pore domain K(+) channel, TRESK (TWIK-related spinal cord K(+) channel) is reversibly activated by the calcium/calmodulin-dependent protein phosphatase, calcineurin. Czirják et al (1) reported that 14-3-3 proteins directly bind to the intracellular loop of TRESK and control the kinetics of the calcium-dependent regulation of the channel. Phosphorylation of serine 264 in mouse TRESK was required for the binding of 14-3-3eta. Because 14-3-3 proteins are ubiquitous, they are expected to control the duration of calcineurin-mediated TRESK activation in all the cell types that express the channel, depending on the phosphorylation state of serine 264 (1). This kind of direct control of channel regulation by 14-3-3 is unique within the 2-pore domain K(+) channel family (1).
Czirják et al (2) reported that calcineurin also interacts with TRESK via an NFAT-like docking site, in addition to its enzymatic action. In its intracellular loop, mouse TRESK possesses the amino acid sequence, PQIVID, which is similar to the calcineurin binding consensus motif, PXIXIT (where X denotes any amino acids), necessary for NFAT (nuclear factor of activated T cells) activation and nuclear translocation (2). Mutations of the PQIVID sequence of TRESK to PQIVIA, PQIVAD, or PQAVAD increasingly deteriorated the calcium-dependent activation in the listed order and correspondingly reduced the benzocaine sensitivity (a property discriminating activated channels from resting ones) when it was measured after the calcium signal in Xenopus oocytes. Microinjection of VIVIT peptide, designed to inhibit the NFATcalcineurin interaction specifically, also eliminated TRESK activation. The intracellular loop of TRESK, expressed as a GST fusion protein, bound constitutively active calcineurin in vitro (2). PQAVAD mutation as well as addition of VIVIT peptide to the reaction abrogated this calcineurin binding. Wild type calcineurin was recruited to GST-TRESK-loop in the presence of calcium and calmodulin. Czirják and colleagues (2) suggested that their results indicated that the PQIVID sequence is a docking site for calcineurin, and its occupancy is required for the calcium-dependent regulation of TRESK.

In the K2P channel family, there are 6 subfamilies according to the differences in channel structure and regulatory mechanism: 1) tandem-pore-domain weakly inward rectifying potassium channels (TWIK), 2) tandem-pore-domain halothane-inhibited potassium channels (THIK), 3) TWIK-related acid-sensitive potassium channels (TASK), 4) tandem-pore-domain alkaline-activated potassium channels (TALK), 5) TWIK-related arachidonic acid-sensitive and mechano-gated potassium channels (TREK), and 6) TWIK-related spinal cord potassium channels (TRESK).

Tandem-pore-domain weakly inward rectifying potassium channels (TWIK)-related spinal cord potassium channels are a kind of 2-pore domain K+ channel (K2P), first discovered in 2003 (3) which is very different from the other K+ channels including voltage-gated (Kv), calcium-activated (Kca), and inward rectifier (Kir) channels in molecular structure, electrophysiological and pharmacological properties (4). K2P is a collection of ion channel subunits exhibiting 4 transmembrane domains (TMA1-4) and 2 pore-forming domains (P1, P2), while other K+ channel subunits are characterized by having 2, 6, or 8 transmembrane segments and one conserved pore-forming domain (5-7). K2P currents are observed at all membrane potentials and can be activated instantaneously by a voltage step and show no voltage threshold for activation, which also distinguishes them from other K+ channels. So, it can produce leak current that help to set and stabilize the resting potential and thus influences the cell excitability under physiological conditions (8,9).

K2P channels may be involved in certain neuropathic pain states. TRESK is specifically located in the spinal cord in humans whereas it is mainly in the dorsal root ganglion (DRG) in mice, where it functions as an important background potassium channel. The major background K+ channel at 24°C in DRG neurons is TRESK (10). Thus, TREKs and TRESK may represent modulatory targets of nociceptive modulation since they likely play active roles in regulating the excitability of DRG neurons.

TRESK is abundantly expressed in the DRG, as well as in the spinal cord (11). The DRG is important in transmitting nociceptive information and in the onset and development of chronic pain because it is a relay of pain signal transport from periphery to the central nervous system. Previous studies have demonstrated hyperexcitability and ectopic discharges of DRG in several pain models, such as chronic constriction injury (CCI) and partial sciatic nerve ligation model (12-14). TRESK may contribute a significant component of background potassium currents in murine dorsal root ganglion neurons (15). Thus, TRESK might play an important role in the development of pain by regulating the background potassium currents of DRG. Also, the glial cell membrane at rest is exclusively permeable to K+ ions whereas the neuron at rest is permeable to both K+ and Na+, so Hunag et al (15) have speculated that the TRESK may be a key ion channel to modulate the resting potential of glial cell. Glia have emerged as important contributor to mechanisms of persistent pain and studies have suggested that glial cells play a key role in nociceptive processes of various pain states (16-20). On activation, both astrocytes and microglia respond to and release a number of signaling molecules, which have protective and/or pathological functions (21). Ca2+-dependent calcineurin is upregulated in reactive astrocytes in neuroinflammatory models (22). Canelliada et al (23) reported that the calcineurin-dependent expression of Cox-2 and Rcan 1-4 is induced (via NFAT activation) by physiological calcium mobilizing agents, such as thrombin, agonists, or purinergic and glutamate receptors, and L-type voltage-
gated calcium channels. Adenovirus-mediated delivery of the NFAT inhibitor, VIVIT, suppressed the IL-1beta-dependent induction of several inflammatory mediators and/or markers of astrocyte activation, including tumor necrosis factor and vimentin (24). Expression of an activated form of calcineurin in one set of astrocyte cultures also triggered the release of factors that, in turn, stimulated NFAT activity in a second set of “naive” astrocytes (24). This effect was prevented when calcineurin-expressing cultures co-expressed VIVIT, an NFAT inhibitor, suggesting that the calcineurin/NFAT pathway coordinates positive feedback signaling between glia (e.g. astrocytes) and perhaps between glia and neurons (24). In quiescent astrocytes, inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha) recruits calcineurin to stimulate a canonical inflammatory pathway involving the transcription factors nuclear factor kappab (NFkappab) and nuclear factor of activated T-cells (NFAT) (25). However, in reactive astrocytes, local anti-inflammatory mediators such as insulin-like growth factor 1 also recruit calcineurin but, in this case, to inhibit NFkappab/NFAT (25). In vitro experiments showed that expression of constitutively active calcineurin in astrocytes abrogated the inflammatory response after TNF-alpha or endotoxins and markedly enhanced neuronal survival (25). Regulation of constitutively active calcineurin in astrocytes abrogated the inflammatory response after TNF-alpha or endotoxins and markedly enhanced neuronal survival (25).

Basic Science of Calcineurin-Inhibitor (CI)-Induced Nociception

Sato et al (35) studied the effects of cyclosporine on pain, using the tail-immersion assay to study the pain response (36,37). Four hours after intraperitoneal injection of cyclosporine (1, 10, and 60 mg/kg), the tails of the mice were immersed 2 cm in water of 48°C and the latency time to a rapid tail flick was measured 5 separate times on each animal over a 15-minute period allowing a 3 – 4 minute recovery period between each trial. To prevent injury, the tail was removed from the water within 10 seconds if the animal did not respond. The times for each animal in each group were then averaged to yield a group mean and standard deviations for comparisons (35).

The Calcineurin-Inhibitor, (Cyclosporine), Enhances Pain Reactions

After administration of cyclosporine (10 and 60 mg/kg), tail-flick latencies in the tail immersion test were significantly shortened in both wild-type $F(3,63) = 13.18, P < 0.001$ and knockout mice $F(3,68) = 15.00, P < 0.001$ by one-way ANOVA (30). Two-way ANOVA showed no significant differences between wild-type and knockout mice $F(1,130) = 2.59, P = 0.11$, indicating that cyclosporine induces hyperalgesia in both
wild-type and multidrug resistant 1 (mdr1) homozygous knockout mice (mdr-1%). (The mdr1 gene encodes for P-glycoprotein, which acts to impede agents like cyclosporine from entering the brain [35].) Knockout mice are genetically engineered mice in which one or more normally existing genes have been inactivated or turned off (“knocked out”) in every cell (generally via replacement or disruption).

Sato and colleagues (35) then tested whether cyclosporine would modulate pain responses in wild-type and mdr1a knockout mice. There are several previous studies demonstrating pain sensitivities in mdr1a knockout mice. For example, Thompson et al (38) found that morphine induced greater analgesia in P-glycoprotein knockout mice compared with that in wild-type mice, whereas Scott et al (39) showed that systemic ondansetron increased pain sensitivity in P-glycoprotein knockout mice but had no effect in wild-type mice. Sato et al (35) found that cyclosporine induces hyperalgesia; however, there were no significant differences between wild-type and knockout mice. Therefore, these results suggest that either cyclosporine has a peripheral effect rather than a central effect or that a sufficient quantity reaches the central nervous systems to have hyperalgesic action (35). Thus, Sato and colleagues (35) speculated that the direct action of cyclosporine on peripheral nerves for pain perception might be related to the pathogenesis of calcineurin-inhibitor-induced neuropathic pain in humans.

**Fig. 1. Potential mechanism of calcineurin-inhibitor (CI)-induced pain.**

**Fig. 1. Potential mechanism of calcineurin-inhibitor (CI)-induced pain.**

Calcineurin-Inhibitors May Affect Nociceptive NO Pathways

Consistent with the findings of Sato et al (36), cyclosporine was shown to attenuate the antinociceptive effects of morphine by activation of a nitric oxide (NO) pathway (40). It has been demonstrated
that cyclosporine reduces catalytic activity of neuronal NO synthase (nNOS) via inhibition of calcineurin-mediated dephosphorylation of nNOS and decreases the production of NO (41,42). nNOS is localized in the peripheral and central nervous systems, although the sites of cyclosporine actions remain unclear. However, desensitization of capsaicin-evoked currents is greatly reduced by cyclosporine in cultured dorsal root ganglion neurons (43).

Calcineurin/Calcineurin-Inhibitors May Regulate Nociceptive Processes Involving TRPV1

The vanilloid receptor TRPV1, a polymodal non-selective cation channel of nociceptive sensory neurons involved in the perception of inflammatory pain, exhibits desensitization in a Ca2+-dependent manner upon repeated activation by capsaicin or protons (44). Mohapatra and Nau (44) generated point mutations at PKA and protein kinase C consensus sites and studied wild type (WT) and mutant channels transiently expressed in HEK293t or HeLa cells under whole cell voltage clamp. Mohapatra and Nau (44) concluded that calcium-dependent desensitization of TRPV1 might be in part regulated through channel dephosphorylation by calcineurin and channel phosphorylation by PKA possibly involving Thr370 as a key amino acid residue.

Calcineurin-inhibitors May Modulate GABA Receptors and the NMDA Receptor Complex

The neurotoxic effects of Cs, such as selective toxicity to glial cells (45) and the induction of apoptosis in oligodendrocytes (46), have been investigated; however, the mechanisms leading to neuropathic pain and causing the allodynia that occurs in the legs remains unclear. The above-mentioned high venous pressure in the lower limbs may have affected not only the bones but also the peripheral nervous system. According to Sander et al (47), Cs have been reported to modulate the activity of both N-methyl-D-aspartate (NMDA) and γ-aminobutyric acid (GABA) receptors. These mechanisms may play a role in contributing to the neuropathic pain-like characteristics of the pain in patients with CIPS, or, alternatively, an unknown neural impairment induced by Cs may have been involved. The itching seen in the area affected by the pain may also have arisen from damage to the peripheral nervous system caused by the Cs. Considering the apparent differences between the features in the patient reported by Noda and colleagues (30) and the others reported, it is tempting to speculate that the pain of CIPS in HSC transplant patients treated with FK might have a pathogenesis and mechanism—which may cause neuropathic pain—that differ from those previously reported for patients with solid organ transplants treated with FK. The use of calcium channel blockers is recommended for the therapy of CIPS because of the ability of these agents to antagonize CSP- or FK-related vasoconstriction (48); however, oral nifedipine had no analgesic effect in the patient of Noda and colleagues (30). Pain relief was obtained for the patient of Noda et al (30) by the administration of intravenous lidocaine combined with oral amitriptyline and clonazepam.

Clinical Science of CI-induced Pain

Aside from the preclinical work which supports the phenomena of CI-induced nociception, it appears that Cs promote pain when used clinically in human subjects. There are multiple case reports of calcineurin-inhibitor induced pain syndrome (CIPS) (34,49-55).

CIPS is an established entity, characterized by severe pain in the lower limbs, frequently with symmetrical involvement, accompanied by radiographic evidence of patchy osteoporosis of bone, bone marrow edema on MRI, and increased uptake on bone scan (48,55). This rare syndrome was first described in organ transplant recipients (56). The pathogenesis remains unclear, but vascular disturbance of bone perfusion and permeability associated with high levels of CSP or FK has been postulated (48,57). Although Kida and colleagues (55) could not perform a thorough radiological examination, they felt that typical clinical symptoms such as debilitating bilateral lower limb pain with preceding intolerable pruritis suggested the diagnosis of CIPS, despite that some of these features might also be seen in patients with complex regional pain syndrome (CRPS) (58,59).

Molina et al (60) reported 9 patients treated with the CI sirolimus who presented with symptoms, clinical findings/features, and scintigraphy changes typical for CRPS. The syndrome was moderate or benign in 8 cases, with total resolution of the symptoms in an average of 3 months without having to modify the SRL dose; the treatment most used was calcitriol at doses of 0.25-0.50 µg per day. Only one patient had intense pain, functional incapacity, erythema, and edema of the affected areas, which remitted immediately after the SRL was replaced by tacrolimus (60).

Fujii et al (33) described a patient with calcineurin
inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation. The patient developed dysesthesia, electric shock-like pain, and severe itching followed by intractable analgesic-resistant pain in the lower extremities. There were no abnormal radiographic findings and there was no improvement with a reduction of CI dosage or with administration of a calcium channel blocker (33).

**Calcineurin as a Mediator Signaling in Nociceptive Pathways**

Calcineurin may also play a role as a signaling mediator in pronociceptive pathways largely via its role in promoting the activation of nuclear factor of activated T-cells (NFAT).

NFAT activation of gene transcription is regulated by Ca2+ (61). In unstimulated cells, NFAT is phosphorylated and restricted to the cytoplasm. After an increase in [Ca2+]i, cytoplasmic NFAT is dephosphorylated by the Ca2+-dependent serine/threonine phosphatase calcineurin (62). This exposes a nuclear localization signal, allowing NFAT to translocate to the nucleus and initiate transcription through interaction with other transcription factors. Four isoforms of NFAT (NFAT1–4) transcription factors have been identified, several of which have been localized to neuronal tissue (63,64), including DRG neurons (65). Increases in [Ca2+]i and activation of NFAT-mediated transcription have been implicated in the maintenance of pain in response to substance P in spinal neurons (66).

In neurons expressing a green fluorescent protein (GFP)-NFAT4 fusion protein, a 2-minute exposure to bradykinin induced the translocation of GFP-NFAT4 from the cytoplasm to the nucleus (67). Translocation was partially inhibited by the removal of extracellular Ca2+ and was blocked by inhibition of calcineurin (67).

---

**Fig. 2. Potential mechanisms of calcineurin-regulated NFAT dependent pronociceptive signaling.**
Furthermore, bradykinin triggered a concentration-dependent increase in NFAT-mediated transcription but more of a luciferase-based NFAT gene reporter (ED50 = 24.4 +/- 0.1 nM) which was dependent on the B2 receptor, PLC activation, and inositol triphosphate-mediated Ca2+ release (67). The use of a dual-luciferase (firefly)-based gene reporter assay (known as Promega) (reporter of NFAT activity [pNFAT-luciferase] where the expression of firefly luciferase was normalized to constitutively expressed R. reniformis luciferase activity to correct for differences in transfection efficiency), enabled investigators to reasonably easily assess NFAT activity (67). Quantitative reverse transcription-polymerase chain reaction data indicated that bradykinin elicited an increase in cyclooxygenase mRNA. This increase was sensitive to calcineurin and B2 receptor inhibition. These findings suggest a mechanism by which short-lived bradykinin-mediated stimuli can enact lasting changes in nociceptor function and sensitivity (67).

Neurotrophins have been shown to activate members of the calcineurin (CaN)-regulated, nuclear factor of activated T-cells (NFATc) family of transcription factors within brain (68). Groth et al (68) hypothesized that NFATc transcription factors couple neurotrophin signaling to gene expression within primary afferent and spinal neurons brain. In situ hybridization revealed NFATc4 mRNA within the dorsal root ganglion and spinal cord. In cultured dorsal root ganglion cells, NGF triggered NFAT-dependent and NFAT-independent transcription in a CaN-sensitive manner. Further, increased BDNF expression following NGF treatment relied on CaN, thereby suggesting that NGF regulated BDNF transcription via activation of NFATc4. Within cultured spinal cells, BDNF also activated CaN-dependent, NFAT-regulated gene expression. Interestingly, BDNF stimulation increased the expression of the pro-nociceptive genes cyclooxygenase-2, neurokinin-1 receptor, inositol trisphosphates receptor type 1, and BDNF itself, through both NFAT-dependent and NFAT-independent transcriptional mechanisms of the brain (68). Groth and colleagues (68) suggested that regulation of pro-nociceptive genes via activation of NFAT-dependent transcription is one mechanism by which NGF and BDNF signaling contributes to the development of persistent pain states in the brain.

Substance P activated NFAT-dependent gene transcription in primary cultures of neonatal rat spinal cord transiently transfected with a luciferase DNA report construct (66). The effect of Substance P was mediated by neuronal neurokinin-1 receptors that coupled to activation of protein kinase C, L-type voltage-dependent calcium channels and calcineurin (66). Substance P had no effect on cyclic AMP response element (CRE)-dependent gene expression, however, calcitonin gene-related peptide, which activated CRE-dependent gene expression, did not activate NFAT signaling (66).

NFAT-mediated transcription plays a role in neuronal development and synaptic plasticity (69). Jackson and colleagues (67) reported that bradykinin, a pronociceptive peptide secreted from the site of injury, activates NFAT signaling in DRG neurons resulting in NFAT-dependent transcription of COX2. Seybold and colleagues (66) reported that NGF and BDNF, pronociceptive neurotrophins, also activate NFAT-dependent transcription. It is likely that the NFAT pathway might not only be activated in the development phase of neuropathic pain as a result of the action of multiple proinflammatory molecules, but also in the maintenance phase where activity and Ca2+-dependent transcription takes place (69). Activation of diverse transcriptional pathways, including NFAT might turn on the transcription of a cohort of genes responsible for sustained hyperexcitability of the DRG in neuropathic pain (69).

**Summary**

Calcineurin may play various roles in modulating nociception depending on clinical/environmental circumstances. Calcineurin may contribute to normal glial resting membrane potential and interruption of this function may facilitate pronociceptive processes. Furthermore, calcineurin may be involved in the pronociceptive signaling of nuclear factor of activated T-cells (NFAT). NFAT may promote the transcription of pronociceptive genes as well as upregulation of pronociceptive chemokine receptors in the dorsal root ganglion. Thus, it appears that calcineurin functions may promote or dampen nociceptive processes. An appreciation of the various aspects of calcineurin function may be important in addressing suboptimal pain control in certain patients under certain circumstances.
References


33. Fujiji N, Ikeda K, Koyama M, Akiyama H, Sakamaki H. Calcineurin-


44. Mohapatra DP, Nau C. Regulation of


